Shire plc accelerating new product sales drive revenue growth of 36%
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 â a year which has seen significant growth in launched products.
Financial Highlights, 2007 Full Year:
Read more ...
New price reductions for GSK antiretrovirals in the world's poorest countries
GSK today announced significant new price reductions for its HIV medicines offered on a not-for-profit basis to the world's poorest countries. This reduction is the fifth time the company has made a price reduction as part of its pioneering preferential pricing policy originally introduced in 1997.
Read more ...
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, for the fourth quarter of 2007 compared to a net loss of $20.7 million, or $0.47 per share, in the same period in the prior year.
Read more ...
Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that a Phase III trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the study would not meet its primary endpoint of improved overall survival.
Read more ...
Trasylol® - One Thousand Lives A Month
A renowned researcher estimates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago. Scott Pelley reports. CBSNews.com
Read more ...
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to US$44 million, comprising an upfront fee and development milestones, plus royalties on future sales.
Read more ...
FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
Boehringer Ingelheim's investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivotal trial programme studying BIBW 2992 in a non-small cell lung cancer (NSCLC) patient group where prior treatment with reversible EGFR inhibitors has failed.
Read more ...